Original Article
Male Circumcision for the Prevention of HSV-2 and HPV Infections and Syphilis
N Engl J Med 2009; 360:1298-1309March 26, 2009
- Abstract
Background
Male circumcision significantly reduced the incidence of human immunodeficiency virus (HIV) infection among men in three clinical trials. We assessed the efficacy of male circumcision for the prevention of herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) infections and syphilis in HIV-negative adolescent boys and men.
Methods
We enrolled 5534 HIV-negative, uncircumcised male subjects between the ages of 15 and 49 years in two trials of male circumcision for the prevention of HIV and other sexually transmitted infections. Of these subjects, 3393 (61.3%) were HSV-2–seronegative at enrollment. Of the seronegative subjects, 1684 had been randomly assigned to undergo immediate circumcision (intervention group) and 1709 to undergo circumcision after 24 months (control group). At baseline and at 6, 12, and 24 months, we tested subjects for HSV-2 and HIV infection and syphilis, along with performing physical examinations and conducting interviews. In addition, we evaluated a subgroup of subjects for HPV infection at baseline and at 24 months.
Results
At 24 months, the cumulative probability of HSV-2 seroconversion was 7.8% in the intervention group and 10.3% in the control group (adjusted hazard ratio in the intervention group, 0.72; 95% confidence interval [CI], 0.56 to 0.92; P=0.008). The prevalence of high-risk HPV genotypes was 18.0% in the intervention group and 27.9% in the control group (adjusted risk ratio, 0.65; 95% CI, 0.46 to 0.90; P=0.009). However, no significant difference between the two study groups was observed in the incidence of syphilis (adjusted hazard ratio, 1.10; 95% CI, 0.75 to 1.65; P=0.44).
Conclusions
In addition to decreasing the incidence of HIV infection, male circumcision significantly reduced the incidence of HSV-2 infection and the prevalence of HPV infection, findings that underscore the potential public health benefits of the procedure. (ClinicalTrials.gov numbers, NCT00425984 and NCT00124878.)
Media in This Article
Figure 1
Enrollment and Outcomes in the Evaluation of Herpes Simplex Virus Type 2 (HSV-2) Infection.Figure 2
Kaplan–Meier Estimates of the Probability of Detection of Herpes Simplex Virus Type 2 (HSV-2) Infection at 24 Months.Article Activity
- Article
Herpes simplex virus type 2 (HSV-2) and human papillomavirus (HPV) infections and syphilis are common sexually transmitted infections. HSV-2 infection and syphilis are two of the main causes of genital ulceration1-3 and have been associated with an increased risk of human immunodeficiency virus (HIV) infection in observational studies.1,2,4 The prevalence of HPV is significantly increased in developing nations.5 HPV infection can cause genital warts, and high-risk HPV genotypes are associated with penile and anal cancer, as well as with cervical cancer in female partners.5,6
Three randomized trials and multiple observational studies showed that male circumcision significantly decreased the incidence of HIV infection in male subjects.7-9 The rate of self-reported genital ulcer disease was decreased among circumcised men in a trial conducted in Rakai, Uganda, which suggested that male circumcision might reduce the incidence and prevalence of ulcerative sexually transmitted infections.7 However, previous findings with regard to the effects of male circumcision on the incidence of HSV-2 infection and syphilis have been more equivocal. Two observational studies suggested that male circumcision significantly decreased the incidence of HSV-2 infection,10,11 whereas other studies showed no association.12-15 Similarly, two observational studies showed that male circumcision decreased the incidence of syphilis,16,17 whereas other studies showed no association.15,18 According to a meta-analysis of circumcision studies, among male subjects who had been circumcised, the odds ratio for HSV-2 infection was 0.88 (95% confidence interval [CI], 0.77 to 1.01), and the odds ratio for syphilis was 0.67 (95% CI, 0.54 to 0.83), as compared with those who had not been circumcised.19 Although most observational studies have suggested that male circumcision decreases the incidence of penile HPV infection,20,21 some studies have shown no effect.22,23
Many of the observational studies evaluating male circumcision and sexually transmitted infections had limited statistical power, were vulnerable to confounding by sexual practices correlated with a high risk of transmission, and evaluated the status of circumcision solely on the basis of self-report. Thus, the potential efficacy of male circumcision for the prevention of sexually transmitted infections can be determined only in randomized trials. We used data from randomized, controlled trials of male circumcision for the prevention of HIV infection in Rakai, Uganda, to assess the efficacy of male circumcision for the prevention of HSV-2 and HPV infections and syphilis in adolescent boys and men.
Methods
Study Design and Subjects
We conducted two parallel but independent trials of male circumcision for the prevention of HIV infection and other sexually transmitted infections in Rakai, Uganda, as described previously.7,24 In the first trial (Rakai-1, which was funded by the National Institutes of Health), we enrolled 4996 HIV-negative, uncircumcised boys and men between the ages of 15 and 49 years who accepted voluntary HIV counseling and testing and agreed to learn their HIV results. The second trial (Rakai-2, which was funded by the Bill and Melinda Gates Foundation) had as its primary goal the assessment of the safety of male circumcision and its effects on sexually transmitted infections in HIV-infected men and their partners. However, the latter trial also included 595 HIV-negative subjects, of whom 155 (26.1%) declined to learn their HIV results and 440 (73.9%) agreed to learn their HIV results but were included in the study to provide blinding of subjects' HIV status so as to prevent potential stigmatization of HIV-infected subjects who were participating in the trial.
The two trials, which were conducted concurrently, had identical protocols. At each visit, all subjects were offered free HIV counseling and testing, health education, and condoms. All subjects who were found to be HIV-positive were referred to an HIV treatment program funded by the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). All subjects provided written informed consent.
Both the Rakai-1 and Rakai-2 trials were approved by four institutional review boards: the Science and Ethics Committee of the Uganda Virus Research Institute (Entebbe, Uganda), the HIV subcommittee of the National Council for Science and Technology (Kampala, Uganda), the Committee for Human Research at Johns Hopkins University's Bloomberg School of Public Health (Baltimore, MD), and the Western Institutional Review Board (Olympia, WA). The Rakai-1 trial was overseen by the data and safety monitoring board for vaccine safety and prevention of the National Institutes of Health and by a separate board for Rakai-2.
We performed physical examinations and conducted interviews to ascertain sociodemographic characteristics and rates of sexual practices at baseline and at 6, 12, and 24 months. Additional details on the study design, specimen testing, and analyses are presented in the Supplementary Appendix, available with the full text of this article at NEJM.org.
Virus and Syphilis Detection
HSV-2 testing was performed with the use of an enzyme-linked immunosorbent assay (ELISA) (Kalon Biological). On the basis of previous evaluation of test performance in Ugandan serum samples, subjects who had positive tests for HSV-2 had an optical-density index value of 1.5 or more,25 and all seroconversions that were detected by ELISA were confirmed by Western blot (Euroimmun). HIV status was determined with the use of two separate ELISAs and confirmed by HIV-1 Western blot analysis, as described previously.7
HPV genotyping was performed with the use of the HPV Linear Array (Roche Diagnostics), as described previously.26,27 HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were considered the primary high-risk (carcinogenic) genotypes.28,29 (We included HPV genotype 66 [HPV-66] in our definition of carcinogenic HPV genotypes after its reclassification, in 2005.29) For the primary analyses of HPV prevalence, we excluded subjects who were HPV-negative and had no detectable beta-globin in the sample, since the presence of cellular material could not be demonstrated.
Active Treponema pallidum infection was determined by means of a positive rapid plasma reagin test (Becton Dickinson) or a toluidine red unheated serum test (TRUST) (New Horizons Diagnostics) and was confirmed by a positive T. pallidum particle agglutination assay (Serodia TP-PA kit, Fujirebio).
Statistical Analysis
For end points for HSV-2 infection and syphilis, we performed time-to-event analyses, using the protocol-specified Kaplan–Meier method, with the end point defined as the time to the detection of HSV-2 or syphilis seropositivity, with censoring of data at the last visit. In the primary intention-to-treat analysis, we performed an adjustment for baseline characteristics using a Cox proportional-hazards model for the time to detection of HSV-2 or syphilis seropositivity. In secondary analyses, adjustments were also made for the trial (Rakai-1 or Rakai-2), changes in sexual practices (number of sexual partners, condom use, and alcohol use with sexual intercourse), and symptoms of sexually transmitted infections (genital ulcers, urethral discharge, and dysuria) during follow-up as time-varying covariates. In addition, we conducted an as-treated analysis in which crossover subjects (i.e., subjects in the intervention group who did not undergo surgery and those in the control group who underwent surgery elsewhere) were classified according to their actual circumcision status.
We used Poisson regression to estimate incidence-rate ratios, risk ratios for prevalence, and 95% confidence intervals. Additional details regarding subgroup analyses of the incidence of HSV-2 infection according to covariates and HPV analysis are available in the Supplementary Appendix. The rates of sexual practices and symptoms of sexually transmitted infections were tabulated at each follow-up visit, and differences between the two study groups were assessed with the use of chi-square tests. All reported P values are two-sided and have not been adjusted for multiple testing.
Results
Subjects
Subjects were enrolled in the Rakai-1 trial from September 2003 through September 2005 and in the Raiki-2 trial from February 2004 through December 2006. Of the 6396 subjects who were initially screened in both the Rakai-1 and Rakai-2 trials, 3003 were excluded from the analyses reported here because of preexisting positive or indeterminate HSV-2 or HIV-1 status (Figure 1Figure 1
Enrollment and Outcomes in the Evaluation of Herpes Simplex Virus Type 2 (HSV-2) Infection.). For the analysis to determine HSV-2 seroconversion, we evaluated 3393 HIV-negative, HSV-2–negative, uncircumcised subjects between the ages of 15 and 49 years; of these subjects, 1684 had been randomly assigned to undergo immediate circumcision (intervention group) and 1709 to undergo circumcision in 24 months (control group). The retention rates at 24 months were 81.9% (1370 of 1673 subjects) in the intervention group and 82.0% (1395 of 1701) subjects in the control group.For the HSV-2 study population, baseline sociodemographic characteristics and rates of sexual practices and symptoms of sexually transmitted infections were similar in the two study groups (Table 1Table 1
Baseline Characteristics, Sexual Practices, and Symptoms of Sexually Transmitted Infections in the Evaluation of Herpes Simplex Virus Type 2 (HSV-2) Infection.). Subjects who were enrolled in the Rakai-2 trial had higher sexual-risk profiles at enrollment than subjects in the Rakai-1 trial because the Rakai-2 trial permitted enrollment of subjects who declined to learn their HIV status, whereas the Rakai-1 trial required receipt of HIV results. The Rakai-2 subjects were significantly older than those in the Rakai-1 trial, were more likely to be currently or previously married, had had a higher number of sexual partners in the previous year, and had had a higher rate of alcohol use with sex in the previous 6 months.Male Circumcision and HSV-2 Acquisition
At 24 months in the intention-to-treat population, HSV-2 infection was detected in 114 subjects in the intervention group and in 153 subjects in the control group (Figure 2Figure 2
Kaplan–Meier Estimates of the Probability of Detection of Herpes Simplex Virus Type 2 (HSV-2) Infection at 24 Months.). The cumulative probability of HSV-2 infection during the 24-month period was lower in the intervention group (7.8%) than in the control group (10.3%) with an unadjusted hazard ratio of 0.75 (95% CI, 0.60 to 0.94; P=0.02). After adjustment for enrollment characteristics and rates of sexual practices and symptoms of sexually transmitted infections, the hazard ratio was 0.72 (95% CI, 0.56 to 0.92; P=0.008). After adjustment for time-varying covariates during follow-up, the hazard ratio was 0.77 (95% CI, 0.62 to 0.97; P=0.03). In the as-treated analysis, the unadjusted hazard ratio for detection of infection was 0.73 (95% CI, 0.59 to 0.93; P=0.01); after adjustment for baseline characteristics, the hazard ratio was 0.72 (95% CI, 0.59 to 0.91; P=0.009).In separate analyses of data from the Rakai-1 and Rakai-2 trials, male circumcision reduced the incidence of HSV-2 infection in both trials. In the Rakai-1 trial, the cumulative probability of HSV-2 infection at 24 months in the intention-to-treat population was lower in the intervention group (7.7%) than in the control group (9.9%), with an unadjusted hazard ratio of 0.77 (95% CI, 0.59 to 0.99). In the Rakai-2 trial, the cumulative probability of HSV-2 infection was 8.6% in the intervention group and 14.0% in the control group (unadjusted hazard ratio, 0.59; 95% CI, 0.27 to 1.27). There was no significant difference in efficacy between the Rakai-1 trial and the Rakai-2 trial (P=0.52 for interaction).
The cumulative rates of HSV-2 seroconversion per 100 person-years, sexual practices, and symptoms of sexually transmitted infections are shown in Figure 3Figure 3
Incidence of Herpes Simplex Virus Type 2 (HSV-2) Infection and Incidence-Rate Ratios, According to Sociodemographic and Clinical Characteristics.. Overall, the incidence of HSV-2 infection was lower among circumcised subjects, and there were no significant differences in the hazard ratios in subgroup analyses. Subjects who reported symptoms of sexually transmitted infections had a higher incidence of HSV-2 infection than asymptomatic subjects. At 24 months, the cumulative prevalence rates of self-reported symptoms of genital ulcer disease were higher among subjects with HSV-2 seroconversion (10.3%) than among subjects without seroconversion (2.7%) (relative risk, 3.78; 95% CI, 2.87 to 4.98; P<0.001).For the HSV-2 study population, rates of sexual practices that were stratified according to circumcision status are shown in Table 2Table 2
Rates of Sexual Risk Behavior in the Evaluation of Herpes Simplex Virus Type 2 (HSV-2) Infection.. At 6 months, reported condom use was higher in the intervention group than in the control group (P<0.001), but no significant differences between the two study groups were observed thereafter. There were no significant between-group differences in the reported number of sexual partners, but nonmarital sexual relationships were more frequently reported by subjects in the intervention group than in the control group, and these differences were significant at 12 and 24 months (P=0.04 and P=0.03, respectively). At all follow-up intervals, rates of reported alcohol use with sexual intercourse were higher in the control group than in the intervention group, differences that were significant at 6, 12, and 24 months. Reported transactional sexual intercourse (which was defined as the exchange of sex for money or gifts) was infrequent, and rates did not differ significantly between the two study groups. Genital ulcer disease was more frequent in the control group than in the intervention group at 6 months (P<0.001), 12 months (P<0.001), and 24 months (P=0.02). However, there were no significant differences between the two groups in reported genital discharge or dysuria.Male Circumcision and Acquisition of Syphilis
To determine the efficacy of circumcision in preventing syphilis, subjects who tested negative for HIV and T. pallidum infections at baseline were evaluated for active T. pallidum infection during follow-up. Enrollment characteristics were similar in the two study groups. At 24 months, syphilis was detected in 50 of 2083 subjects (2.4%) in the intervention group, as compared with 45 of 2143 subjects (2.1%) in the control group (hazard ratio, 1.14; 95% CI, 0.77 to 1.75; P=0.50). Adjustment for enrollment characteristics and rates of sexual practices and symptoms of sexually transmitted infections did not significantly affect these estimates of circumcision efficacy (adjusted hazard ratio, 1.10; 95% CI, 0.75 to 1.65; P=0.44).
Male Circumcision and Prevalence of HPV
Overall, baseline sociodemographic characteristics and rates of sexual practices and symptoms of sexually transmitted infections were similar in the two study groups for subjects in the HPV substudy population (see the table in the Supplementary Appendix). At enrollment, the prevalence of high-risk HPV genotypes was 38.1% in the intervention group and 37.1% in the control group (P=0.79).
In the primary intention-to-treat analyses at 24 months, high-risk HPV genotypes were detected in 42 of 233 subjects in the intervention group (18.0%), as compared with 80 of 287 subjects in the control group (27.9%), with an unadjusted risk ratio of 0.65 (95% CI, 0.45 to 0.94; P=0.01) (Table 3Table 3
Male Circumcision and the Prevalence of Human Papillomavirus (HPV) Infection.). Adjustment for enrollment characteristics and rates of sexual practices and symptoms of sexually transmitted infections did not significantly affect this estimate (adjusted risk ratio, 0.65; 95% CI, 0.46 to 0.90; P=0.009). When the analysis was confined to subjects who had beta-globin–positive samples at the 24-month visit, high-risk HPV genotypes were detected in 32 of 215 subjects (14.9%) in the intervention group, as compared with 69 of 260 subjects (26.5%) in the control group (risk ratio, 0.56; 95% CI, 0.37 to 0.85; P=0.007). At 24 months, multiple high-risk HPV genotypes were detected in 10 of 233 subjects (4.3%) in the intervention group and in 35 of 287 subjects (12.2%) in the control group (risk ratio, 0.35; 95% CI, 0.17 to 0.71; P=0.004). The prevalence of non–high-risk HPV genotypes at the 24-month visit was also lower in the intervention group (26.2%) than in the control group (39.4%) (risk ratio, 0.66; 95% CI, 0.49 to 0.91; P=0.01).Discussion
In our study, the circumcision of adolescent boys and men in a rural Ugandan population significantly reduced the incidence of HSV-2 infection and the prevalence of HPV infection during 24 months of follow-up but did not affect the incidence of syphilis. The efficacies of circumcision for the prevention of HSV-2 incidence and HPV prevalence were 25% and 35%, respectively. Adjustment resulted in a modest increase in efficacy to 28% for HSV-2 infection but did not change efficacy for HPV infection. These findings are compatible with those of observational studies, in which reduced rates of HSV-2 and HPV infections were associated with circumcision,10,11,19-21 and with the results of one clinical trial, which showed that circumcision decreased the risk of HPV infection.30,31 These findings, in conjunction with those of previous trials, indicate that circumcision should now be accepted as an efficacious intervention for reducing heterosexually acquired infections with HSV-2, HPV, and HIV in adolescent boys and men. However, it must be emphasized that protection was only partial, and it is critical to promote the practice of safe sex.
The biologic mechanisms for the reduction in rates of HSV-2 and HPV infections by means of circumcision may involve anatomical factors, cellular factors, or both. The retraction of the foreskin over the shaft during intercourse exposes the inner preputial mucosa to vaginal and cervical fluids7,19,32 and can also result in microtears during intercourse, particularly in the frenulum.7,19,32 The moist subpreputial cavity may provide a favorable environment for the survival of HSV-2 and HPV and consequent epithelial infection.7,19,33 Both HSV-2 and HPV replicate in epithelial cells of the epidermis and dermis,34 and the inner mucosa of the foreskin is lightly keratinized, which may facilitate the access of HSV-2 and HPV to underlying epithelial cells in uncircumcised adolescent boys and men. After circumcision and keratinization of the surgical scar, the risk of such epithelial infection is probably reduced.
In observational studies,2,35 genital HSV-2 infection has been associated with an increased risk of HIV acquisition. In our trial, we found that male circumcision reduced the rate of symptomatic genital ulcerative disease.7 Since genital ulcerative disease and HSV-2 infection are both thought to be cofactors in HIV acquisition,2,36,37 male circumcision may provide protection against HIV acquisition by reducing the risk of HSV-2 infection and its associated genital ulcers. However, the possibility of confounding because of sexual practices correlated with a high risk of transmission cannot be excluded. Two trials of HSV-2 suppression in HSV-2–positive, HIV-negative subjects did not show protection against HIV acquisition,38,39 which suggests that more research is required on the acquisition of HSV-2 and HIV infections.
With respect to the use of circumcision to prevent HPV infection, our study was limited, since it was confined to a subgroup of subjects who were observed both at enrollment and at 24 months. In both the intervention and control groups, these subjects may represent a self-selected population of compliant subjects who could be at lower risk for HPV infection than the general population; this factor could result in an underestimation of the efficacy of male circumcision. Also, since samples were evaluated only at 24 months, we were limited in our ability to determine whether the reduced HPV prevalence after circumcision was due to a reduced rate of HPV acquisition, an increased rate of HPV clearance, or both. Nevertheless, these findings, in conjunction with data from observational studies20,21 and one trial in South Africa,31 demonstrate the efficacy of circumcision in decreasing the prevalence of HPV in adolescent boys and men.
Male circumcision has now been shown to decrease the rates of HIV, HSV-2, and HPV infections in men and of trichomoniasis and bacterial vaginosis in their female partners.7-9,40 Circumcision also reduces symptomatic ulceration in HIV-negative men and women and HIV-positive men.7,24,40 Thus, male circumcision reduces the risk of several sexually transmitted infections in both sexes, and these benefits should guide public health policies for neonatal, adolescent, and adult male circumcision programs.
Supported by grants from the National Institutes of Health (U01-AI-51171), the Bill and Melinda Gates Foundation (22006.02), and the Fogarty International Center (5D43TW001508 and D43TW00015) and by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases.
Dr. Gravitt reports receiving research funding from Roche Molecular Diagnostics, which manufactured the HPV genotyping test used in this study. No other potential conflict of interest relevant to this article was reported.
Drs. Quinn and Gray contributed equally to this article.
This article (10.1056/NEJMoa0802556) was updated on March 2, 2011, at NEJM.org.
This study is dedicated to the memory of Blake Charvat, who died on August 21, 2008.
We thank Andrew Redd for his suggestions; Jordyn Gamiel, Jessica Neal, Roslyn Howard, and Lauren Wilson for their technical assistance; and the study participants and the Rakai Community Advisory Board, whose commitment and cooperation made this study possible.
Source Information
From the Departments of Pathology (A.A.R.T.) and Medicine (T.C.Q., O.L., A.E.O., S.J.R.), School of Medicine, and the Departments of Epidemiology and Molecular Microbiology and Immunology (P.E.G., R.G.N.), Population, Family, and Reproductive Health (B.C., M.Z.C., M.J.W., R.H.G.), and International Health and Biostatistics (L.H.M.), Bloomberg School of Public Health, Johns Hopkins University, Baltimore; the Institute of Public Health, Makerere University, Kampala (D.S.), and Rakai Health Sciences Program, Entebbe (G.K., V.S.) — both in Uganda; and the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD (T.C.Q., O.L., M.R., S.J.R.).
Address reprint requests to Dr. Quinn at the Rangos Building, Rm. 530, 855 N. Wolfe St., Baltimore, MD 21205, or at tquinn@jhmi.edu.
- References
References
1
Whitley RJ ,Roizman B . Herpes simplex virus infections. Lancet 2001;357:1513-1518
CrossRef | Web of Science | Medline2
Corey L ,Wald A ,Celum CL ,Quinn TC . The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr 2004;35:435-445
CrossRef | Web of Science | Medline3
Fenton KA ,Breban R ,Vardavas R , et al. Infectious syphilis in high-income settings in the 21st century. Lancet Infect Dis 2008;8:244-253
CrossRef | Web of Science | Medline4
Serwadda D ,Gray RH ,Sewankambo NK , et al. Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda. J Infect Dis 2003;188:1492-1497
CrossRef | Web of Science | Medline5
de Sanjose S ,Diaz M ,Castellsague X , et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-459
CrossRef | Web of Science | Medline6
Munoz N ,Bosch FX ,de Sanjose S , et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527
Full Text | Web of Science | Medline7
Gray RH ,Kigozi G ,Serwadda D , et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007;369:657-666
CrossRef | Web of Science | Medline8
Bailey RC ,Moses S ,Parker CB , et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007;369:643-656
CrossRef | Web of Science | Medline9
Auvert B ,Taljaard D ,Lagarde E ,Sobngwi-Tambekou J ,Sitta R ,Puren A . Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005;2:e298-e298[Erratum, PLoS Med 2006;3(5):e298.]
CrossRef | Web of Science | Medline10
Auvert B ,Buve A ,Lagarde E , et al. Male circumcision and HIV infection in four cities in sub-Saharan Africa. AIDS 2001;15:Suppl 4:S31-S40
CrossRef | Web of Science | Medline11
Weiss HA ,Buve A ,Robinson NJ , et al. The epidemiology of HSV-2 infection and its association with HIV infection in four urban African populations. AIDS 2001;15:Suppl 4:S97-S108
CrossRef | Web of Science | Medline12
Xu F ,Markowitz LE ,Sternberg MR ,Aral SO . Prevalence of circumcision and herpes simplex virus type 2 infection in men in the United States: the National Health and Nutrition Examination Survey (NHANES), 1999-2004. Sex Transm Dis 2007;34:479-484
Web of Science | Medline13
Lavreys L ,Rakwar JP ,Thompson ML , et al. Effect of circumcision on incidence of human immunodeficiency virus type 1 and other sexually transmitted diseases: a prospective cohort study of trucking company employees in Kenya. J Infect Dis 1999;180:330-336
CrossRef | Web of Science | Medline14
Reynolds SJ ,Shepherd ME ,Risbud AR , et al. Male circumcision and risk of HIV-1 and other sexually transmitted infections in India. Lancet 2004;363:1039-1040
CrossRef | Web of Science | Medline15
Gray R ,Azire J ,Serwadda D , et al. Male circumcision and the risk of sexually transmitted infections and HIV in Rakai, Uganda. AIDS 2004;18:2428-2430
Web of Science | Medline16
Bwayo J ,Plummer F ,Omari M , et al. Human immunodeficiency virus infection in long-distance truck drivers in east Africa. Arch Intern Med 1994;154:1391-1396
CrossRef | Web of Science | Medline17
Cook LS ,Koutsky LA ,Holmes KK . Circumcision and sexually transmitted diseases. Am J Public Health 1994;84:197-201
CrossRef | Web of Science | Medline18
Urassa M ,Todd J ,Boerma JT ,Hayes R ,Isingo R . Male circumcision and susceptibility to HIV infection among men in Tanzania. AIDS 1997;11:73-80
Web of Science | Medline19
Weiss HA ,Thomas SL ,Munabi SK ,Hayes RJ . Male circumcision and risk of syphilis, chancroid, and genital herpes: a systematic review and meta-analysis. Sex Transm Infect 2006;82:101-109
CrossRef | Web of Science | Medline20
Baldwin SB ,Wallace DR ,Papenfuss MR , et al. Human papillomavirus infection in men attending a sexually transmitted disease clinic. J Infect Dis 2003;187:1064-1070
CrossRef | Web of Science | Medline21
Castellsague X ,Bosch FX ,Munoz N , et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002;346:1105-1112
Full Text | Web of Science | Medline22
Shin HR ,Franceschi S ,Vaccarella S , et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004;190:468-476
CrossRef | Web of Science | Medline23
Weaver BA ,Feng Q ,Holmes KK , et al. Evaluation of genital sites and sampling techniques for detection of human papillomavirus DNA in men. J Infect Dis 2004;189:677-685
CrossRef | Web of Science | Medline24
Wawer M, Kigozi G, Serwadda D, et al. Trial of male circumcision in HIV+ men, Rakai, Uganda: effects in HIV+ men and in women partners. In: Proceedings of the 15th Conference on Retroviruses and Opportunistic Infections, Boston, February 3–6, 2008.
25
Gamiel JL ,Tobian AAR ,Laeyendecker OB , et al. Improved performance of enzyme-linked immunosorbent assays and the effect of human immunodeficiency virus coinfection on the serologic detection of herpes simplex virus type 2 in Rakai, Uganda. Clin Vaccine Immunol 2008;15:888-890
CrossRef | Web of Science | Medline26
Gravitt PE ,Peyton CL ,Alessi TQ , et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000;38:357-361
Web of Science | Medline27
Gravitt PE ,Peyton CL ,Apple RJ ,Wheeler CM . Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol 1998;36:3020-3027
Web of Science | Medline28
Bosch FX ,Manos MM ,Munoz N , et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995;87:796-802
CrossRef | Web of Science | Medline29
Cogliano V ,Baan R ,Straif K ,Grosse Y ,Secretan B ,El Ghissassi F . Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204-204
CrossRef | Web of Science | Medline30
Sobngwi-Tambekou J, Taljaard D, Lissouba P, et al. Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 2009;199 (in press).
31
Auvert B ,Sobngwi-Tambekou J ,Cutler E , et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009;199:14-19
CrossRef | Web of Science | Medline32
Szabo R ,Short RV . How does male circumcision protect against HIV infection? BMJ 2000;320:1592-1594
CrossRef | Web of Science | Medline33
McCoombe SG ,Short RV . Potential HIV-1 target cells in the human penis. AIDS 2006;20:1491-1495
CrossRef | Web of Science | Medline34
Gupta R ,Warren T ,Wald A . Genital herpes. Lancet 2007;370:2127-2137
CrossRef | Web of Science | Medline35
Gray RH ,Wawer MJ ,Brookmeyer R , et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001;357:1149-1153
CrossRef | Web of Science | Medline36
Corey L ,Adams HG ,Brown ZA ,Holmes KK . Genital herpes simplex virus infections: clinical manifestations, course, and complications. Ann Intern Med 1983;98:958-972
Web of Science | Medline37
Corey L ,Handsfield HH . Genital herpes and public health: addressing a global problem. JAMA 2000;283:791-794
CrossRef | Web of Science | Medline38
Celum C ,Wald A ,Hughes J , et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 2008;371:2109-2119
CrossRef | Web of Science | Medline39
Watson-Jones D ,Weiss HA ,Rusizoka M , et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008;358:1560-1571
Full Text | Web of Science | Medline40
Gray RH, Kigozi G, Serwadda D, et al. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol 2009;200(1):42.e1-42.e7.
- Citing Articles (82)
Citing Articles
1
Ginesa Albero, Xavier Castellsagué, Anna R. Giuliano, Francesc Xavier Bosch. (2012) Male Circumcision and Genital Human Papillomavirus. Sexually Transmitted Diseases 39:2, 104-113
CrossRef2
Showket Hussain, Mausumi Bharadwaj, Vilas Nasare, Malasha Kumari, Shashi Sharma, Suresh Hedau, Bhudev C. Das. (2012) Human papillomavirus infection among young adolescents in India: Impact of vaccination. Journal of Medical Virology 84:2, 298-305
CrossRef3
Nicola Zetola, Jeffrey D. Klausner. (2012) Male Circumcision Reduces Human Papillomavirus Incidence and Prevalence. Sexually Transmitted Diseases 39:2, 114-115
CrossRef4
A. A. R. Tobian, G. Kigozi, A. D. Redd, D. Serwadda, X. Kong, A. Oliver, F. Nalugoda, T. C. Quinn, R. H. Gray, M. J. Wawer. (2012) Male Circumcision and Herpes Simplex Virus Type 2 Infection in Female Partners: A Randomized Trial in Rakai, Uganda. Journal of Infectious Diseases 205:3, 486-490
CrossRef5
Stephen A. Zderic, Sarah M. Lambert. 2012. Developmental Abnormalities of the Genitourinary System. , 1191-1204.
CrossRef6
Deepak Saxena, Yihong Li, Liying Yang, Zhiheng Pei, Michael Poles, William R. Abrams, Daniel Malamud. (2011) Human Microbiome and HIV/AIDS. Current HIV/AIDS Reports
CrossRef7
J. M. Marrazzo, W. Cates. (2011) Interventions to Prevent Sexually Transmitted Infections, Including HIV Infection. Clinical Infectious Diseases 53:suppl 3, S64-S78
CrossRef8
Aaron A.R. Tobian, Xiangrong Kong, Patti E. Gravitt, Kevin P. Eaton, Godfrey Kigozi, David Serwadda, Amy E. Oliver, Fred Nalugoda, Frederick Makumbi, Michael Z. Chen, Maria J. Wawer, Thomas C. Quinn, Ronald H. Gray. (2011) Male circumcision and anatomic sites of penile high-risk human papillomavirus in Rakai, Uganda. International Journal of Cancer 129:12, 2970-2975
CrossRef9
Zhong-Min Ma, Brandon F. Keele, Huma Qureshi, Mars Stone, Veronique DeSilva, Linda Fritts, Jeffrey D. Lifson, Christopher J. Miller. (2011) SIVmac251 Is Inefficiently Transmitted to Rhesus Macaques by Penile Inoculation with a Single SIV env Variant Found in Ramp-up Phase Plasma. AIDS Research and Human Retroviruses 27:12, 1259-1269
CrossRef10
Carolyn Gardella. (2011) Herpes Simplex Virus Genital Infections: Current Concepts. Current Infectious Disease Reports 13:6, 588-594
CrossRef11
Thomas C. Quinn. (2011) The 30-Year War on AIDS: Have We Reached the Tipping Point?. Sexually Transmitted Diseases 38:12, 1089-1093
CrossRef12
Katrine Lundsby, Tania Dræbel, Dan Wolf Meyrowitsch. (2011) ‘It brought joy in my home as in the area of my wife.’ How recently circumcised adult men ascribe value to and make sense of male circumcision. Global Public Health1-15
CrossRef13
Zixin Wang, Joseph T. F. Lau, Jing Gu. (2011) Acceptability of Circumcision Among Clients of Female Sex Worker in Hong Kong. AIDS and Behavior
CrossRef14
Stênio de Cássio Zequi, Gustavo Cardoso Guimarães, Francisco Paulo da Fonseca, Ubirajara Ferreira, Wagner Eduardo de Matheus, Leonardo Oliveira Reis, Giuliano Amorim Aita, Sidney Glina, Victor Silvestre Soares Fanni, Marjo Denisson Cardenuto Perez, Luiz Renato Montez Guidoni, Valdemar Ortiz, Lucas Nogueira, Luis Carlos de Almeida Rocha, Gustavo Cuck, Walter Henriques da Costa, Ravendra Ryan Moniz, José Hipólito Dantas Jr., Fernando Augusto Soares, Ademar Lopes. (2011) Sex with Animals (SWA): Behavioral Characteristics and Possible Association with Penile Cancer. A Multicenter Study. The Journal of Sexual Medicineno-no
CrossRef15
Kelley VanBuskirk, Rachel L. Winer, James P. Hughes, Qinghua Feng, Yuzo Arima, Shu-Kuang Lee, Michael E. Stern, Sandra F. OʼReilly, Laura A. Koutsky. (2011) Circumcision and Acquisition of Human Papillomavirus Infection in Young Men. Sexually Transmitted Diseases 38:11, 1074-1081
CrossRef16
N. Larke, S. L. Thomas, I. dos Santos Silva, H. A. Weiss. (2011) Male Circumcision and Human Papillomavirus Infection in Men: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases 204:9, 1375-1390
CrossRef17
Joseph E. Tota, Myriam Chevarie-Davis, Lyndsay A. Richardson, Maaike deVries, Eduardo L. Franco. (2011) Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. Preventive Medicine 53, S12-S21
CrossRef18
Kennedy N Otwombe, Kathleen J Sikkema, Janan Dietrich, Guy de Bruyn, Martin van der Watt, Glenda E Gray. (2011) Willingness to Participate in Biomedical HIV Prevention Studies After the HVTN 503/Phambili Trial: A Survey Conducted Among Adolescents in Soweto, South Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes 58:2, 211-218
CrossRef19
Dan Danielsson, Per Kristen Teigen, Harald Moi. (2011) The genital econiche: focus on microbiota and bacterial vaginosis. Annals of the New York Academy of Sciences 1230:1, 48-58
CrossRef20
AR Giuliano, MF Schim van der Loeff, AG Nyitray. (2011) Circumcised HIV-infected men and HPV transmission. The Lancet Infectious Diseases 11:8, 581-582
CrossRef21
Aaron AR Tobian, Xiangrong Kong, Maria J Wawer, Godfrey Kigozi, Patti E Gravitt, David Serwadda, Kevin P Eaton, Fred Nalugoda, Thomas C Quinn, Ronald H Gray. (2011) Circumcision of HIV-infected men and transmission of human papillomavirus to female partners: analyses of data from a randomised trial in Rakai, Uganda. The Lancet Infectious Diseases 11:8, 604-612
CrossRef22
Aaron AR Tobian, Ronald H Gray. (2011) Male foreskin and oncogenic human papillomavirus infection in men and their female partners. Future Microbiology 6:7, 739-745
CrossRef23
Nancy S Padian, Sandra I McCoy, Salim S Abdool Karim, Nina Hasen, Julia Kim, Michael Bartos, Elly Katabira, Stefano M Bertozzi, Bernhard Schwartländer, Myron S Cohen. (2011) HIV prevention transformed: the new prevention research agenda. The Lancet 378:9787, 269-278
CrossRef24
Ruanne V Barnabas, Judith N Wasserheit, Yunda Huang, Holly Janes, Rhoda Morrow, Jonathan Fuchs, Karen E Mark, Martin Casapia, Devan V Mehrotra, Susan P Buchbinder, Lawrence Corey. (2011) Impact of Herpes Simplex Virus Type 2 on HIV-1 Acquisition and Progression in an HIV Vaccine Trial (the Step Study). JAIDS Journal of Acquired Immune Deficiency Syndromes 57:3, 238-244
CrossRef25
Joseph Monsonego. (2011) Male circumcision for prevention of oncogenic HPV infection – Author's reply. The Lancet 378:9788, 315
CrossRef26
Deborah Anderson, Joseph A. Politch, Jeffrey Pudney. (2011) HIV Infection and Immune Defense of the Penis. American Journal of Reproductive Immunology 65:3, 220-229
CrossRef27
Minh H. Dinh, Kelly M. Fahrbach, Thomas J. Hope. (2011) The Role of the Foreskin in Male Circumcision: An Evidence-Based Review. American Journal of Reproductive Immunology 65:3, 279-283
CrossRef28
K. E. Johnson, A. D. Redd, T. C. Quinn, A. N. Collinson-Streng, T. Cornish, X. Kong, R. Sharma, A. A. R. Tobian, B. Tsai, M. E. Sherman, G. Kigozi, D. Serwadda, M. J. Wawer, R. H. Gray. (2011) Effects of HIV-1 and Herpes Simplex Virus Type 2 Infection on Lymphocyte and Dendritic Cell Density in Adult Foreskins from Rakai, Uganda. Journal of Infectious Diseases 203:5, 602-609
CrossRef29
Fati Kirakoya-Samadoulougou, Nicolas Nagot, Marie-Christine Defer, Seydou Yaro, Paulin Fao, François Ilboudo, Youssouf Langani, Nicolas Meda, Annie Robert. (2011) Epidemiology of Herpes Simplex Virus Type 2 Infection in Rural and Urban Burkina Faso. Sexually Transmitted Diseases 38:2, 117-123
CrossRef30
Brian J. Morris, Ronald H. Gray, Xavier Castellsague, F. Xavier Bosch, Daniel T. Halperin, Jake H. Waskett, Catherine A. Hankins. (2011) The Strong Protective Effect of Circumcision against Cancer of the Penis. Advances in Urology 2011, 1-21
CrossRef31
Danielle M. Backes, Maaike C.G. Bleeker, Chris J.L.M. Meijer, Michael G. Hudgens, Kawango Agot, Robert C. Bailey, J.O. Ndinya-Achola, Juma Hayombe, Cornelis J.A. Hogewoning, Stephen Moses, Peter J.F. Snijders, Jennifer S. Smith. (2011) Male circumcision is associated with a lower prevalence of human papillomavirus-associated penile lesions among Kenyan men. International Journal of Cancern/a-n/a
CrossRef32
Richard G Wamai, Brian J Morris, Stefan A Bailis, David Sokal, Jeffrey D Klausner, Ross Appleton, Nelson Sewankambo, David A Cooper, John Bongaarts, Guy de Bruyn, Alex D Wodak, Joya Banerjee. (2011) Male circumcision for HIV prevention: current evidence and implementation in sub-Saharan Africa. Journal of the International AIDS Society 14:1, 49
CrossRef33
Dipankar Biswas, Biswajyoti Borkakoty, Jagadish Mahanta, Kamini Walia, Lahari Saikia, Brogen S Akoijam, Lobsang Jampa, Alia Kharkongar, Eric Zomawia. (2011) Seroprevalence and risk factors of herpes simplex virus type-2 infection among pregnant women in Northeast India. BMC Infectious Diseases 11:1, 325
CrossRef34
Maria J Wawer, Aaron AR Tobian, Godfrey Kigozi, Xiangrong Kong, Patti E Gravitt, David Serwadda, Fred Nalugoda, Frederick Makumbi, Victor Ssempiija, Nelson Sewankambo, Stephen Watya, Kevin P Eaton, Amy E. Oliver, Michael Z Chen, Steven J Reynolds, Thomas C Quinn, Ronald H Gray. (2011) Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. The Lancet 377:9761, 209-218
CrossRef35
Andrew Mujugira, Amalia S Magaret, Jared M Baeten, Connie Celum, Jairam Lingappa. (2011) Risk Factors for HSV-2 Infection among Sexual Partners of HSV-2/HIV-1 Co-Infected Persons. BMC Research Notes 4:1, 64
CrossRef36
E. Vardas, A. R. Giuliano, S. Goldstone, J. M. Palefsky, E. D. Moreira, M. E. Penny, C. Aranda, H. Jessen, H. Moi, D. G. Ferris, K.-L. Liaw, J. B. Marshall, S. Vuocolo, E. Barr, R. M. Haupt, E. I. O. Garner, D. Guris. (2011) External Genital Human Papillomavirus Prevalence and Associated Factors Among Heterosexual Men on 5 Continents. Journal of Infectious Diseases 203:1, 58-65
CrossRef37
Chloé Tarnaud, Pascale Lissouba, Ewalde Cutler, Adrian Puren, Dirk Taljaard, Bertran Auvert. (2011) Association of Low-Risk Human Papillomavirus Infection with Male Circumcision in Young Men: Results from a Longitudinal Study Conducted in Orange Farm (South Africa). Infectious Diseases in Obstetrics & Gynecology 2011, 1-7
CrossRef38
Cecily Banura, Florence M Mirembe, Anne R Katahoire, Proscovia B Namujju, Anthony K Mbonye, Fred M Wabwire. (2011) Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. Infectious Agents and Cancer 6:1, 11
CrossRef39
Anna R Giuliano, Alan G Nyitray, Ginesa Albero. (2011) Male circumcision and HPV transmission to female partners. The Lancet 377:9761, 183-184
CrossRef40
Nienke J Veldhuijzen, Peter JF Snijders, Peter Reiss, Chris JLM Meijer, Janneke HHM van de Wijgert. (2010) Factors affecting transmission of mucosal human papillomavirus. The Lancet Infectious Diseases 10:12, 862-874
CrossRef41
Maximo O. Brito, Maximiliano Luna, Robert C. Bailey. (2010) The feasibility and acceptability of male circumcision among men, women, and health providers of the Altagracia Province, Dominican Republic. AIDS Care 22:12, 1530-1535
CrossRef42
Laith J. Abu-Raddad, Joshua T. Schiffer, Rhoda Ashley, Ghina Mumtaz, Ramzi A. Alsallaq, Francisca Ayodeji Akala, Iris Semini, Gabriele Riedner, David Wilson. (2010) HSV-2 serology can be predictive of HIV epidemic potential and hidden sexual risk behavior in the Middle East and North Africa. Epidemics 2:4, 173-182
CrossRef43
Puneet Masson, Philip S. Li, Mark A. Barone, Marc Goldstein. (2010) The ShangRing device for simplified adult circumcision. Nature Reviews Urology 7:11, 638-642
CrossRef44
Howard H Kim, Philip S Li, Marc Goldstein. (2010) Male circumcision: Africa and beyond?. Current Opinion in Urology 20:6, 515-519
CrossRef45
Helen A Weiss, Kim E Dickson, Kawango Agot, Catherine A Hankins. (2010) Male circumcision for HIV prevention: current research and programmatic issues. AIDS 24:Suppl 4, S61-S69
CrossRef46
John R. Brill. (2010) Sexually Transmitted Infections in Men. Primary Care: Clinics in Office Practice 37:3, 509-525
CrossRef47
Tim Hargreave. (2010) Male circumcision: towards a World Health Organisation normative practice in resource limited settings. Asian Journal of Andrology 12:5, 628-638
CrossRef48
Yifeng Peng, Puneet Masson, Philip S. Li, Yue Chang, Long Tian, Richard Lee, Howard Kim, David C. Sokal, Marc Goldstein. (2010) No-Needle Local Anesthesia for Adult Male Circumcision. The Journal of Urology 184:3, 978-983
CrossRef49
T. Young, N. Siegfried, M. Muller, J. Deeks, J. Volmink, R. Gray, A. Tobian, G. Kigozi, M. Wawer, D. Serwadda, E. Pisani. (2010) Cochrane Column. International Journal of Epidemiology 39:4, 968-972
CrossRef50
Paul F Austin. (2010) Circumcision. Current Opinion in Urology 20:4, 318-322
CrossRef51
David J Templeton. (2010) Male circumcision to reduce sexual transmission of HIV. Current Opinion in HIV and AIDS 5:4, 344-349
CrossRef52
Suzanne M. Garland. (2010) Prevention strategies against human papillomavirus in males. Gynecologic Oncology 117:2, S20-S25
CrossRef53
Alok C Bharti, Shirish Shukla, Sutapa Mahata, Suresh Hedau, Bhudev C Das. (2010) Human papillomavirus and control of cervical cancer in India. Expert Review of Obstetrics & Gynecology 5:3, 329-346
CrossRef54
C. M. Wetmore, L. E. Manhart, J. N. Wasserheit. (2010) Randomized Controlled Trials of Interventions to Prevent Sexually Transmitted Infections: Learning From the Past to Plan for the Future. Epidemiologic Reviews 32:1, 121-136
CrossRef55
Jared M Baeten, Deborah Donnell, Saidi H Kapiga, Allan Ronald, Grace John-Stewart, Mubiana Inambao, Rachel Manongi, Bellington Vwalika, Connie Celum. (2010) Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples. AIDS 24:5, 737-744
CrossRef56
Minh H Dinh, Michael D McRaven, ZL Kelley, Sudhir Penugonda, Thomas J Hope. (2010) Keratinization of the adult male foreskin and implications for male circumcision. AIDS 24:6, 899-906
CrossRef57
Damon R. Jameson, Connie L. Celum, Lisa Manhart, Timothy W. Menza, Matthew R. Golden. (2010) The Association Between Lack of Circumcision and HIV, HSV-2, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men. Sexually Transmitted Diseases 37:3, 147-152
CrossRef58
David J Templeton, Gregorio A Millett, Andrew E Grulich. (2010) Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men. Current Opinion in Infectious Diseases 23:1, 45-52
CrossRef59
Musa Otieno Ng’ayo, David Friedrich, King K. Holmes, Elizabeth Bukusi, Rhoda Ashley Morrow. (2010) Performance of HSV-2 type specific serological tests in men in Kenya. Journal of Virological Methods 163:2, 276-281
CrossRef60
Živilė Gudlevičienė, Alė Smilgevičiūtė-Ivshin, Aurelija Vaitkuvienė, Agnė Šepetienė, Janina Didžiapetrienė. (2010) Human papillomavirus and other risk factors in Lithuanian cervical carcinoma patients. Acta medica Lituanica 17:3, 106-115
CrossRef61
Guy de Bruyn, Neil A Martinson, Glenda E Gray. (2010) Male circumcision for HIV prevention: developments from sub-Saharan Africa. Expert Review of Anti-infective Therapy 8:1, 23-31
CrossRef62
David G. Regan, David J. Philp, Edward K. Waters. (2010) Unresolved questions concerning human papillomavirus infection and transmission: a modelling perspective. Sexual Health 7:3, 368
CrossRef63
Sean M. Doyle, James G. Kahn, Nap Hosang, Peter R. Carroll. (2010) The Impact of Male Circumcision on HIV Transmission. The Journal of Urology 183:1, 21-26
CrossRef64
P. Modiano. (2009) Quoi de neuf en thérapeutique dermatologique ?. Annales de Dermatologie et de Vénéréologie 136, S445-S459
CrossRef65
Nicholas J. Van Wagoner, William M. Geisler, James M. Sizemore, Richard Whitley, Edward W. Hook. (2009) Herpes Simplex Virus in African American Heterosexual Males: The Roles of Age and Male Circumcision. Sexually Transmitted Diseases1
CrossRef66
Helen A Weiss, Catherine A Hankins, Kim Dickson. (2009) Male circumcision and risk of HIV infection in women: a systematic review and meta-analysis. The Lancet Infectious Diseases 9:11, 669-677
CrossRef67
Jared M Baeten, Connie Celum, Thomas J Coates. (2009) Male circumcision and risk of HIV in women – Authors' reply. The Lancet 374:9700, 1498
CrossRef68
Kristine E Johnson, Mark E Sherman, Victor Ssempiija, Aaron AR Tobian, Jonathan M Zenilman, Maire A Duggan, Godfrey Kigozi, David Serwadda, Maria J Wawer, Thomas C Quinn, Charles S Rabkin, Ronald H Gray. (2009) Foreskin inflammation is associated with HIV and herpes simplex virus type-2 infections in Rakai, Uganda. AIDS 23:14, 1807-1815
CrossRef69
Robert S Van Howe, Michelle R Storms. (2009) Circumcision to prevent HPV infection. The Lancet Oncology 10:8, 746-747
CrossRef70
P. Roumeguère. (2009) Ulcérations anales des infections sexuellement transmissibles. Côlon & Rectum 3:3, 137-145
CrossRef71
(2009) Male Circumcision for the Prevention of HSV-2 and HPV Infections. New England Journal of Medicine 361:3, 307-308
Full Text72
Aaron AR Tobian, Victor Ssempijja, Godfrey Kigozi, Amy E Oliver, David Serwadda, Frederick Makumbi, Frederick K Nalugoda, Boaz Iga, Steven J Reynolds, Maria J Wawer, Thomas C Quinn, Ronald H Gray. (2009) Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. AIDS 23:12, 1589-1594
CrossRef73
F. T. Serota. (2009) Male Circumcision Associated With Reduced Risk of HSV-2 and HPV. AAP Grand Rounds 22:1, 9-9
CrossRef74
Aaron AR Tobian, Thomas C Quinn. (2009) Herpes simplex virus type 2 and syphilis infections with HIV: an evolving synergy in transmission and prevention. Current Opinion in HIV and AIDS 4:4, 294-299
CrossRef75
Jared M Baeten, Connie Celum, Thomas J Coates. (2009) Male circumcision and HIV risks and benefits for women. The Lancet 374:9685, 182-184
CrossRef76
Ronald H. Gray. (2009) Infectious disease: Male circumcision for preventing HPV infection. Nature Reviews Urology 6:6, 298-299
CrossRef77
Sarah S Wilson, Esra Fakioglu, Betsy C Herold. (2009) Novel approaches in fighting herpes simplex virus infections. Expert Review of Anti-infective Therapy 7:5, 559-568
CrossRef78
Jacyntha A. Sterling. (2009) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 44:6, 526-532
CrossRef79
Lisa Richards. (2009) Male circumcision: HSV-2 and HPV. Nature Reviews Urology 6:5, 239-239
CrossRef80
Jorge Sanchez, Javier R Lama, Jesus Peinado, Andres Paredes, Aldo Lucchetti, Kevin Russell, Tadeusz Kochel, Jose L Sebastian. (2009) High HIV and Ulcerative Sexually Transmitted Infection Incidence Estimates Among Men Who Have Sex With Men in Peru: Awaiting for an Effective Preventive Intervention. JAIDS Journal of Acquired Immune Deficiency Syndromes 51:Supplement 1, S47-S51
CrossRef81
Peter H Kilmarx, Katrina Kretsinger, Gregorio A Millett. (2009) Considerations in the role of male circumcision in the prevention of HIV transmission in the USA. HIV Therapy 3:3, 241-254
CrossRef82
Golden, Matthew R., Wasserheit, Judith N., . (2009) Prevention of Viral Sexually Transmitted Infections — Foreskin at the Forefront. New England Journal of Medicine 360:13, 1349-1351
Full Text
- Letters
